Edition:
United States

Arsanis Inc (ASNS.OQ)

ASNS.OQ on NASDAQ Stock Exchange Global Market

15.51USD
20 Apr 2018
Change (% chg)

$0.05 (+0.32%)
Prev Close
$15.46
Open
$15.21
Day's High
$15.78
Day's Low
$15.21
Volume
7,187
Avg. Vol
10,534
52-wk High
$27.83
52-wk Low
$10.50

Chart for

About

Arsanis, Inc. is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company's mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and... (more)

Overall

Beta: --
Market Cap(Mil.): $229.14
Shares Outstanding(Mil.): 14.29
Dividend: --
Yield (%): --

Financials

  ASNS.OQ Industry Sector
P/E (TTM): -- 185.16 33.25
EPS (TTM): -2.88 -- --
ROI: -- -0.71 13.13
ROE: -- -2.76 14.96

BRIEF-Arsanis Inc - Out Licenses Preclinical Stage E. Coli Monoclonal Antibodies

* BB100 SECURED EXCLUSIVE,WORLDWIDE PRECLINICAL DEVELOPMENT LICENSE, OPTION TO DEVELOPMENT, COMMERCIALIZATION LICENSE, TO MABS TARGETING E. COLI Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Apr 04 2018

BRIEF-Arsanis Granted Key Patents For ASN100 Covering Cross-Neutralizing S. Aureus Toxin Antibodies

* ARSANIS GRANTED KEY PATENTS FOR ASN100 COVERING CROSS-NEUTRALIZING S. AUREUS TOXIN ANTIBODIES Source text for Eikon: Further company coverage:

Mar 14 2018

BRIEF-Arsanis Reports Q4 Net Loss $1.68 Per Share

* ARSANIS REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2017

Mar 09 2018

BRIEF-Arsanis Inc Files To Say It Has Raised $20 Million In Equity Financing - SEC Filing

* ARSANIS INC FILES TO SAY IT HAS RAISED $20 MILLION IN EQUITY FINANCING - SEC FILING Source text (http://bit.ly/2AvvJ48) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Dec 04 2017

BRIEF-New Enterprise Associates 16 L.P. Reports 14.6 Percent Stake In Arsanis As Of Nov 20

* NEW ENTERPRISE ASSOCIATES 16 L.P. REPORTS A 14.6 PERCENT STAKE IN ARSANIS AS OF NOVEMBER 20, 2017 - SEC FILING Source text : [ID:http://bit.ly/2ncluP0] Further company coverage:

Nov 29 2017

Earnings vs. Estimates